Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab

BACKGROUND: The use of pharmacokinetics is associated with cost savings in anti-tumor necrosis factor (anti-TNF) therapy, but the long-term cost savings in a large cohort of Crohn's disease (CD) patients are unknown. AIM: The goal of this study was to compare the cost of anti-TNF therapy in two...

Descripción completa

Detalles Bibliográficos
Autores principales: Roblin, Xavier, Attar, Alain, Lamure, Michel, Savarieau, Bernard, Brunel, Pierre, Duru, Gérard, Peyrin-Biroulet, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802699/
https://www.ncbi.nlm.nih.gov/pubmed/27123185
http://dx.doi.org/10.3402/jmahp.v3.29229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802699/
https://www.ncbi.nlm.nih.gov/pubmed/27123185
http://dx.doi.org/10.3402/jmahp.v3.29229

Ejemplares similares